Here's Why Ensign Group Shares Are Attracting Investors Now

The Ensign Group, Inc. ENSG is well-poised for growth, benefiting from a combination of disciplined acquisitions, organic operational improvement and targeted capital investments in healthcare facilities. It has been expanding its portfolio, which now includes 378 healthcare operations, featuring 31 senior living facilities, spread across 17 states.

Headquartered in San Juan Capistrano, CA, ENSG holds a market capitalization of $11.9 billion. The company operates through two reportable segments: Skilled Services and Standard Bearer. It has risen 58% over the past year, outperforming the industry’s average gain of 56.4%.

Courtesy of solid prospects, ENSG currently carries a Zacks Rank #2 (Buy).

Where Do Estimates for ENSG Stand?

The Zacks Consensus Estimate for Ensign Group’s 2026 earnings is pegged at $7.48 per share, indicating a 13.9% year-over-year rise. In the past seven days, it has witnessed one upward estimate revision against none in the opposite direction. Furthermore, the consensus mark for revenues is pegged at $5.8 billion for 2026, implying a 14.1% year-over-year rise. It beat earnings estimates in each of the past four quarters, with an average surprise of 2.9%.

The Ensign Group, Inc. Price, Consensus and EPS Surprise

The Ensign Group, Inc. price-consensus-eps-surprise-chart | The Ensign Group, Inc. Quote

ENSG’s Growth Drivers

Ensign Group’s revenue growth hinges on expanding service revenues from its specialized healthcare portfolio, including skilled nursing, rehabilitation and senior living. The aging U.S. demographic sustains robust demand for these services, bolstering the company's long-term prospects. In 2025, its total revenues rose 18.7% year over year, with 18.8% growth in Service revenues.

ENSG continues to expand by purchasing skilled nursing and post-acute care facilities in multiple markets, often targeting assets with turnaround potential or long-term upside. Recent entries into Alabama and additional acquisitions across Arizona, Washington, California, Idaho, Texas and Wisconsin highlight continued expansion of regional clusters. By integrating these operations into its decentralized model, the company aims to enhance performance through better clinical systems, leadership and local management expertise.

Ensign Group focuses heavily on improving clinical outcomes and building strong relationships with hospitals and healthcare providers in its communities. Better clinical performance helps the company attract more patients and gain the trust of hospitals and health plans, which in turn increases patient volumes and allows facilities to treat more medically complex cases.

Capital investments also play a role in supporting long-term expansion. The company continues to upgrade facilities, add beds and develop new healthcare infrastructure in markets where demand is rising. These initiatives help expand treatment capacity and improve care delivery while allowing Ensign Group to strengthen its presence in established regions.

Ensign Group’s capital strategy supports steady value creation through dividend payments and selective share repurchases. The company has raised its dividend for 23 consecutive years, including a December 2025 increase to 6.5 cents per share. It repurchased shares worth $20 million in 2025. Its total debt is 6% of its capital, which is significantly lower than the industry’s average of 89.7%.

ENSG: Risks to Watch

There are some factors, however, that investors should keep a careful eye on.

The company’s total expenses have escalated over the last several years due to higher costs of services and rent. Total expenses witnessed a year-over-year increase of 12.3% in 2024 and 18.7% in 2025. We expect total expenses to rise 13.6% year over year in 2026. The persistent escalation of expenses might weigh on its margin growth. Ensign Group's valuation looks expensive at the current level. It has a forward 12-month P/S ratio of 2.07X, which compares unfavorably with its five-year median of 1.58X.

Other Stocks to Consider

Some other top-ranked stocks in the Medical space are BrightSpring Health Services, Inc. BTSG, GeneDx Holdings Corp WGS and Phibro Animal Health Corporation PAHC, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.61 per share has witnessed seven upward revisions in the past seven days against no movement in the opposite direction. BrightSpring Health Services beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 40.4%. The consensus estimate for current-year revenues is pegged at $14.8 billion, suggesting 14.8% year-over-year growth.

The Zacks Consensus Estimate for GeneDx Holdings’ current-year earnings of 75 cents per share has witnessed one upward revision in the past 30 days, against no movement in the opposite direction. GeneDx Holdings beat earnings estimates in each of the trailing four quarters, with the average surprise being 164.2%. The consensus estimate for current-year revenues is pegged at $545 million, suggesting 27.5% year-over-year growth.

The Zacks Consensus Estimate for Phibro Animal Health’s current-year earnings of $3.02 per share has witnessed four upward revisions in the past 30 days, against no movement in the opposite direction. Phibro Animal Health beat earnings estimates in each of the trailing four quarters, with an average surprise of 20.2%. The consensus estimate for current-year revenues is pegged at $1.5 billion, suggesting 14.4% year-over-year growth.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report

The Ensign Group, Inc. (ENSG): Free Stock Analysis Report

GeneDx Holdings Corp. (WGS): Free Stock Analysis Report

BrightSpring Health Services, Inc. (BTSG): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research